A single oral compound advancing across four indications: retinal degeneration first, CNS neurodegeneration next.
The mechanism: SBC003 induces neuroglobin expression via p-body modulation — a mutation-agnostic, endogenous pathway that protects neurons regardless of the upstream trigger. One molecule, multiple indications, no injections.
Four programs, one oral pill — no intravitreal injections.
Development Stage
Development Stage
Development Stage
Development Stage
SBC003's four lead indications span retinal degeneration and CNS neurodegeneration. The neurodegenerative therapeutics market is growing at 5.7–7.2% CAGR, driven by aging demographics and the structural shortcomings of the one-target drug paradigm.
Market Size
Significant unmet need
Growth
12.1% CAGR
Patients
2M globally
Unmet need: 99% have no disease-modifying treatment
Market Size
Significant unmet need
Growth
9.3% CAGR
Patients
200M globally
Unmet need: No approved oral treatment; EMA rejected both approved injectables
Market Size
Significant unmet need
Growth
8.8% CAGR
Patients
~2M in US/EU/China/Japan
Unmet need: No approved neuroprotective treatment
Market Size
Significant unmet need
Growth
5.7–7.2% CAGR
Patients
32–38M Alzheimer's, 10M Parkinson's, globally
Unmet need: No approved disease-modifying therapy across all major CNS indications.
No other compound in development combines oral bioavailability, broad-spectrum neuroprotection, and retinal + CNS potential in a single molecule.
Oral Administration
SBC003 is a simple, daily pill.
Mutation-agnostic
Targets the universal neuronal apoptosis pathway downstream of any mutation. Applicable to 100% of RP patients vs. <1% eligible for gene therapies like Luxturna.
Five-protein shield
Published evidence of protection against all five major neurotoxic proteins, amyloid-β, α-synuclein, tau, prion, and amylin, in a single peer-reviewed Aging Cell paper.
Validated in primates
Significant RNFL recovery in rhesus monkeys with naturally occurring optic atrophy at oral doses of 5–50 mg/kg. Plasma concentrations of 47.6–86.4 ng/mL confirmed.
Understand the mechanism of action, preclinical data, and the peer-reviewed evidence supporting SBC003.
SBC003 is investigational and has not been approved by any regulatory authority. This page presents scientific and development-stage information only.
Pioneering first-in-class orally bioavailable compounds to halt neurodegeneration and restore vision. Clinical-stage. Basel, Switzerland.
© 2026 SunRegen Healthcare AG. All rights reserved.
Robinienweg 51, 4153 Reinach, Switzerland
UID: CHE-295.245.274
This website contains forward-looking statements regarding future products, development plans, and business strategies. Actual results may differ materially. Nothing on this site constitutes medical or investment advice.